Health ❯ Healthcare ❯ Clinical Trials

Efficacy Studies

Phase 3 Trials Lecanemab Patient Outcomes Orforglipron Lecanemab Trials Miplyffa Home Treatment Options Non-Inferiority Trials Obesity Treatments Hormone Receptor-Positive Cancer Drug Comparisons AUGMENT-101 Trial Weight Loss Outcomes Amycretin Trials mNEXSPIKE Vaccine Simplify-1 Study Phase IIb/III Trials TRANSCEND FL Study Beamion LUNG-1 Trial Placebo-Controlled Trials Phase-3 Trials H3 K27M Mutations Tirzepatide vs Dulaglutide FRESCO Trials LUNA 3 Study Orforglipron vs Semaglutide Cagrilintide OASIS 4 Trial Analytical Testing Weight Management CheckMate 67T Minoxidil Absorption SURMOUNT and SURPASS STEP Program Progression-Free Survival STEP UP Trials MATTERHORN Trial MONARCH 2 Trial MONARCH 3 Trial Asthma Exacerbations Semaglutide Trials Phase 2 Trials Weight Loss Drugs Acalabrutinib and Bendamustine-Rituximab SELECT Trial Results DREAMM-8 Trial CAPELLA Trial SUMMIT Trial Lecanemab Efficacy Lecanemab Trial Results

FDA Clears GSK’s Exdensur as First Twice-Yearly Add-On for Severe Eosinophilic Asthma

The long-acting IL-5 antibody targets eosinophilic disease with a dosing schedule GSK says could improve adherence.

EMA Panel Backs Higher 7.2 mg Wegovy Dose for Obesity

FDA Approves Breyanzi for Marginal Zone Lymphoma After Two or More Therapies

FDA Approves Durvalumab Added to Perioperative FLOT for Resectable Gastric and GEJ Cancer

FDA Approves Epkinly Monotherapy and Triplet Regimen for Relapsed Follicular Lymphoma

Stevia-Derived Microneedle Patch Boosts Minoxidil in Mouse Hair-Loss Study

FDA Approves Merck’s Enflonsia Monoclonal Antibody for Infant RSV Prevention

FDA Approves Moderna’s mNEXSPIKE for High-Risk Populations